Clinical outcomes of peritoneal dialysis in Southeast Asia: a scoping review protocol with a focused North American comparator Authors: Tina Mai, Joshua Vo, Savinnie Ho, Jewel Ng, Andy Nguyen, Quang Thanh Nguyen Published: 2026 ABSTRACT Abstract AbstractIntroductionPeritoneal dialysis (PD) is delivered across diverse health-system contexts. In Southeast Asia (SEA), PD has been promoted to expand kidney replacement therapy access where haemodialysis capacity, geography and resources constrain care. This protocol describes a scoping review focused on reported PD clinical outcomes in SEA, with North America used only as a prespecified external comparator rather than as a control group, global benchmark or proxy for best practice.Methods and analysisThis scoping review will follow Joanna Briggs Institute guidance and will be reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). PRISMA Protocols (PRISMA-P) items are addressed where applicable. The review will be conducted from 1 May 2026 to 31 October 2026. Searches will identify sources published from 1 January 2000 to the planned final search date of 31 July 2026. MEDLINE, Embase, CENTRAL, Global Index Medicus, Google Scholar, citation searching and selected registry, professional, governmental and conference sources will be searched. No language restriction will be applied at the search stage. Eligible evidence will include peer-reviewed studies, registry or professional reports, governmental or institutional reports and conference abstracts or posters with extractable PD outcome data. Non-English sources will be screened using machine translation and extracted using targeted translation of relevant sections when feasible. Outcomes of interest include patient survival, technique survival and transition to haemodialysis, peritonitis and other infectious complications, hospitalisation and health service utilisation, cardiovascular outcomes, catheter-related complications and patient-reported outcomes when reported as clinical endpoints. Findings will be summarised descriptively and mapped by outcome domain and by region, with contextual factors noted when reported.Ethics and disseminationEthics approval is not required because this review will synthesise published literature only. Findings will be disseminated through peer-reviewed publication and conference presentations, and the extracted dataset and search strategies will be shared in supplementary materials or an online repository, subject to journal policy.Trial registrationThis protocol is registered on the Open Science Framework (OSF): https://osf.io/3dkvx/.Keywords: NEPHROLOGY, Dialysis, End stage renal failure STRENGTHS AND LIMITATIONS OF THIS STUDY This protocol follows established scoping review methodology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) reporting guidance. This protocol follows established scoping review methodology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) reporting guidance. The review is focused on Southeast Asian peritoneal dialysis outcome reporting and uses North America as an external comparator. The review is focused on Southeast Asian peritoneal dialysis outcome reporting and uses North America as an external comparator. A comprehensive, reproducible search strategy will be applied across major biomedical databases and supplemented by reference list screening. A comprehensive, reproducible search strategy will be applied across major biomedical databases and supplemented by reference list screening. Data charting will capture source type, language, translation approach and extraction confidence to support transparent interpretation of non-English and non-indexed evidence. Data charting will capture source type, language, translation approach and extraction confidence to support transparent interpretation of non-English and non-indexed evidence. The review will not perform a full global comparator search; therefore, findings should not be interpreted as representing worldwide or as ranking regions by clinical performance. The review will not perform a full global comparator search; therefore, findings should not be interpreted as representing worldwide or as ranking regions by clinical performance. Background End-stage kidney disease (ESKD) is a major and growing contributor to global morbidity and mortality, driven by population ageing and the increasing prevalence of diabetes, hypertension and other chronic diseases.1 As access to kidney transplantation remains limited in many settings, dialysis continues to be the predominant form of kidney replacement therapy (KRT) worldwide.1 The burden of ESKD is rising particularly rapidly in low- and middle-income regions, including Southeast Asia (SEA), placing increasing strain on health systems that must deliver long-term, resource-intensive care to expanding patient populations.1 2 Peritoneal dialysis (PD) is a well-established dialysis modality used across diverse health system contexts.3 As a home-based therapy, PD offers flexibility and reduced dependence on centralised infrastructure compared with facility-based haemodialysis (HD).4 Consequently, the role of PD varies across regions.5 In several SEA countries, PD has been promoted as a strategic modality to expand dialysis access in the setting of limited HD capacity, geographical barriers and resource constraints.6 7 It is therefore delivered within markedly different policy, organisational and clinical environments across countries in SEA and in other settings.5 6 This contextual variation is highly consequential for interpreting PD clinical outcomes and for judging the transferability of evidence across settings.8,10 Patients initiating PD in SEA may differ systematically from those in other regions with respect to demographics and clinical characteristics, socioeconomic conditions and access to care, reflecting broader differences in health system context.6 11 Health systems in SEA may also vary widely in access to trained nephrology personnel, availability and structure of training programmes and broader workforce capacity to deliver and sustain kidney care.12 Together, these factors may shape observed PD outcomes and complicate direct cross-regional comparisons unless outcome definitions, measurement approaches and study settings are clearly described. Clinical outcomes such as mortality, hospitalisation and technique survival are central to evaluating the safety, effectiveness and sustainability of PD programmes.13 Key outcomes include patient survival, technique survival and transfer to HD, peritonitis and other infectious complications, hospitalisation and health service utilisation, catheter-related complications and health-related quality of life when framed as a clinical endpoint.13 14 These outcomes are frequently used to assess programme performance, guide modality selection and inform policy decisions. However, the literature on PD clinical outcomes in SEA remains fragmented with many studies focusing on a single endpoint, selected subpopulations, individual countries or specific policy interventions. Relevant evidence may also appear outside English-language indexed journals, including non-English publications, conference abstracts, registry reports and professional or governmental documents. A scoping review is therefore warranted to map the extent, range and nature of the evidence; identify commonly assessed outcomes and methodological patterns; and highlight gaps in reporting across publication types and settings. A preliminary search of MEDLINE (PubMed) and Joanna Briggs Institute (JBI) Evidence Synthesis did not identify any existing or ongoing scoping reviews with this specific focus. North American PD literature provides a substantial body of published data and can serve as one bounded external comparator for outcome-domain reporting.9 However, North America should not be interpreted as a control group, a global standard or a proxy for best practice. PD practice, registry infrastructure, quality oversight, payer systems and clinical outcomes vary within North America and across the wider international community. Important PD outcome research, registry reporting and technical innovation have also emerged from regions outside North America, including Europe, China, Japan, Australia, New Zealand and other settings. The present protocol therefore avoids any assumption that North American evidence represents global PD practice or superior clinical performance. A full global comparison of PD outcome reporting would be valuable but would answer a substantially different research question. Such a review would require comprehensive multilingual searching of primary studies, registry reports, professional society documents, conference proceedings and grey literature across multiple regions. A partial global search could introduce additional bias through uneven source coverage. Consistent with scoping review methodology, the present review uses a focused and transparent scope: it maps outcome reporting in SEA and compares the resulting outcome domains with a prespecified North American external comparator literature, while explicitly acknowledging that this comparator is not global. This scoping review therefore aims to map and characterise the existing literature on clinical outcomes of PD among individuals receiving PD in SEA and North America, from the year 2000 to 31 July 2026. By describing reported outcomes, study designs, populations and settings, this review will clarify regional patterns in outcome reporting, identify areas of convergence and divergence and highlight evidence gaps that limit meaningful comparison and context sensitive translation of findings into policy and practice. The resulting evidence map will support interpretation of PD outcome data across different health system contexts and inform future comparative effectiveness research and quality improvement efforts. Research questions Which clinical outcomes of PD are reported in studies from SEA since 2000, and how do these outcome domains compare with those reported in the prespecified North American external comparator literature? Which clinical outcomes of PD are reported in studies from SEA since 2000, and how do these outcome domains compare with those reported in the prespecified North American external comparator literature? How are these outcomes defined and measured across studies in SEA and North America? How are these outcomes defined and measured across studies in SEA and North America? What study designs, populations and care settings are used in studies reporting PD outcomes in SEA and North America? What study designs, populations and care settings are used in studies reporting PD outcomes in SEA and North America? What similarities and differences are described in the reported PD outcomes across SEA and North America, taking into account variation in follow-up duration and analytical approaches? What similarities and differences are described in the reported PD outcomes across SEA and North America, taking into account variation in follow-up duration and analytical approaches? Methods This scoping review will be conducted in accordance with the JBI methodology15 and will be reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR).16 This protocol has also been prepared with reference to PRISMA Protocols (PRISMA-P)17 items where applicable to a scoping review protocol (online supplemental file 1 - PRISMA-P-checklist). The review is planned to start on 1 May 2026 and to be completed by 31 October 2026. The planned final search date is 31 July 2026; searches will include sources published from 1 January 2000 to 31 July 2026. Any substantive protocol amendments will be dated, described and documented in the Open Science Framework record and in the final review report. The primary focus of this review is PD outcome reporting in SEA. North America, defined as the USA, Canada and Mexico, was selected a priori as a focused external comparator to provide a bounded and reproducible contrast in outcome-domain reporting. This comparator is not intended to function as a control group, a quality benchmark, a ranking standard or a representation of global PD practice. The review will not infer that outcomes from North America are superior, more valid or more generalisable than those from SEA or other regions. Eligibility criteria Population This review will include evidence sources involving individuals receiving PD in SEA or North America. Eligible participant groups include adults and children receiving PD, regardless of underlying kidney disease aetiology, PD modality (continuous ambulatory PD or automated PD) or duration of therapy. Studies including mixed KRT populations will be eligible only if PD-specific outcomes are reported separately or can be clearly disaggregated. No restrictions will be placed on age, sex, comorbidity burden or baseline kidney function at dialysis initiation. Sources focused exclusively on healthcare professionals or caregivers without reporting patient-level clinical outcomes will be excluded. Concept This scoping review will consider evidence sources reporting clinical outcomes of PD. Clinical outcomes will include, but will not be limited to, patient survival and all-cause mortality; technique survival, including transfer from PD to HD; peritonitis and other infectious complications, including incidence rates, recurrence, severity and causative organisms; hospitalisation outcomes such as frequency, causes and length of stay; cardiovascular outcomes and related mortality; metabolic and nutritional outcomes; catheter-related complications and catheter removal; health-service utilisation; and patient-reported outcomes when reported as clinical endpoints. The review will also consider outcomes reported after PD-related interventions, training programmes or policy initiatives, provided that clinical outcome data are presented. Studies reporting predictors, risk factors or associations related to PD outcomes will be included when the outcomes of interest are clearly defined and explicitly reported. Context SEA will be defined as Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar (Burma), the Philippines, Singapore, Thailand, Timor-Leste and Vietnam. North America will be defined as the USA, Canada and Mexico. Evidence sources will be eligible if they were conducted entirely within one of these regions or if multinational or multicountry sources reported region-specific or country-level data for at least one SEA or North American country. PD may be delivered in any clinical or community setting, including tertiary hospitals, dialysis centres, satellite units or home-based programmes. No restrictions will be placed on health-system financing models, policy environments or urban and rural locations. Types of evidence sources This scoping review will include a broad range of evidence sources reporting original PD clinical outcome data. Eligible sources will include observational cohort studies, registry-based studies, case–control studies, cross-sectional studies reporting clinical outcomes, programme evaluations, randomised or non-randomised interventional studies, registry or professional body reports, governmental or institutional reports and conference abstracts or posters with extractable PD outcome data. Case reports and small case series with fewer than 10 PD participants will be excluded because their limited sample size is unlikely to inform outcome-reporting patterns relevant to the review questions. Systematic reviews and scoping reviews will be excluded from evidence synthesis, but their reference lists will be screened. Clinical practice guidelines will not be included as primary evidence sources; however, selected international guidelines and registry outcome categories may be used in the contextual outcome-domain check described above. When conference abstracts, posters, registry reports or grey-literature documents appear to overlap with later full-text peer-reviewed publications from the same cohort, the most complete source will be prioritised. Abstracts or reports will be retained only if they provide unique outcome-domain information not available in the full publication. Search strategy The search strategy will aim to identify evidence sources reporting clinical outcomes of PD in SEA and in the focused North American comparator. An initial limited search of MEDLINE (PubMed) and JBI Evidence Synthesis was conducted to identify relevant articles. Text words contained in the titles and abstracts of these articles, together with index terms used to describe them, were used to develop a comprehensive MEDLINE (PubMed) search strategy. The full MEDLINE strategy and the adapted strategies for additional sources are provided in online supplemental table 1a–e. Search reporting will follow PRISMA-S principles18 where applicable. The search will include sources published from 1 January 2000 to the planned final search date of 31 July 2026. This date range was selected to reflect contemporary PD technologies, training practices, infection-prevention protocols and health-system organisation relevant to current clinical practice. Databases will include MEDLINE (PubMed), Embase (Elsevier) and the Cochrane Central Register of Controlled Trials (CENTRAL). Additional searching will include backward and forward citation searching including full-text articles and relevant reviews, Google Scholar screening and targeted searches of relevant registry, professional society, governmental and conference websites. Grey-literature searches will be structured and documented. Sources may include national or regional renal registry reports, dialysis registry reports, professional society publications, ministry or governmental reports, institutional programme reports and publicly accessible conference abstracts or posters from nephrology, dialysis or PD-focused meetings. Because grey-literature availability varies across countries and websites, the final review will report the sources searched, search dates, search strings or browsing paths where feasible and reasons for excluding non-extractable records. Language and translation strategy No language restriction will be applied at the search stage. For non-English records, titles and abstracts will be screened using machine translation, together with English abstracts when available. Potentially eligible non-English sources will undergo targeted translation of the sections required for eligibility assessment and outcome-domain extraction, including abstracts, methods, results, tables, figures and outcome definitions. Full professional translation of all non-English documents will not be required because the primary purpose of the review is to map outcome domains rather than to pool numerical outcome estimates. When interpretation remains uncertain after machine translation and review of tables or figures, corresponding authors will be contacted when contact details are available. Non-English sources will be included when outcome domains can be identified with reasonable confidence. Sources that appear potentially relevant but cannot be extracted with sufficient confidence will be listed separately as potentially relevant but insufficiently extractable, rather than being silently excluded. During charting, reviewers will record the source language, translation approach and extraction-confidence category (high, moderate or low). Study selection Following the search, all retrieved records will be collated and uploaded into Zotero (Corporation for Digital Scholarship, Vienna, Virginia, USA), and duplicates will be removed using the built-in deduplication function and manual verification. Titles and abstracts will then be exported to Microsoft Excel and screened independently by two reviewers against the predefined inclusion criteria. Records that clearly do not pertain to PD, do not report disaggregated PD-specific findings related to clinical outcomes or do not involve study populations from SEA or North America will be excluded at this stage. Records that cannot be confidently excluded based on title and abstract will be retained for full-text or full-source assessment. Full texts or full source documents of potentially relevant records will be retrieved. Full-source screening will be conducted by two reviewer teams working in pairs, with each team independently assessing their assigned records. Any disagreements among reviewer pairs will be resolved through discussion or consultation with a third reviewer. Screening and selection procedures will be conducted manually using Excel as the sole management tool; no automated screening or machine-learning methods will be used. The study selection process will be summarised using a PRISMA-ScR flow diagram, with source categories reported where feasible.16 Data extraction Data will be extracted from included sources using a structured Excel-based data extraction form developed a priori and provided in online supplemental table 2, in accordance with JBI guidance. The data extraction form will be piloted on a subset of included sources and refined iteratively to ensure comprehensive and consistent data capture. Two reviewers will independently extract data from each included source; discrepancies will be resolved by consensus and, if required, adjudicated by a third reviewer. Extracted data will include study or source characteristics (authors, year, journal or source, country or countries, region, study design, setting, publication type, source type, language and translation approach), participant characteristics (population groups, age group, sample size, PD modality and relevant clinical context), PD-related outcomes (reported clinical outcomes, outcome definitions, measurement units, follow-up duration, predictors and risk factors) and authors’ interpretations (stated recommendations, implications and limitations). For non-English or grey-literature sources, extraction confidence will be recorded. When PD-specific data are unclear, incomplete or combined with other KRT modalities, corresponding authors will be contacted for clarification up to two times; unresolved missing information will be recorded transparently in the extraction table and results narrative. Data analysis and presentation Results will be summarised descriptively to reflect the diversity of study designs, populations, source types and reported outcome measures. Given the anticipated heterogeneity of study designs, populations and outcomes, no quantitative pooling or cross-study comparison of effect sizes will be performed. Quantitative findings will be summarised descriptively and organised by country, region, publication type, source type and outcome domain, including mortality, technique survival, peritonitis and other complications, hospitalisation, catheter-related outcomes, modality transfer, health-service utilisation, patient-reported outcomes and other reported clinical endpoints. Findings will be presented according to the a priori analytical structure defined for the review. Regional similarities and differences will be presented narratively where sufficient data are available, with explicit attention to study design, population characteristics, follow-up duration, analytical approaches, source type and health-system context. The North American comparator will be interpreted only as a focused external comparator for outcome-domain reporting. It will not be used to rank regions or infer superior clinical performance. A sensitivity analysis will compare outcome domains identified from English-language indexed full-text peer-reviewed articles with outcome domains identified from non-English sources, grey literature, registry or professional reports and conference abstracts or posters. The purpose of this analysis will be to assess whether the expanded search identifies outcome domains that would have been missed by an English-language indexed full-text search alone. In addition, a targeted contextual check will compare the final outcome-domain framework with selected international PD guideline and registry outcome categories to identify major outcome domains that may not be captured by the focused comparator approach. Consistent with scoping review methodology, no formal risk-of-bias assessment or critical appraisal of included sources will be undertaken. As this review synthesises published and publicly available literature rather than primary participant data, no sample size calculation is applicable. Supplementary material Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-118546). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. References Supplementary Materials